2017
Calreticulin inhibits inflammation‐induced osteoclastogenesis and bone resorption
Fischer CR, Mikami M, Minematsu H, Nizami S, Lee H, Stamer D, Patel N, Soung D, Back JH, Song L, Drissi H, Lee FY. Calreticulin inhibits inflammation‐induced osteoclastogenesis and bone resorption. Journal Of Orthopaedic Research® 2017, 35: 2658-2666. PMID: 28460421, PMCID: PMC8996436, DOI: 10.1002/jor.23587.Peer-Reviewed Original ResearchConceptsRecombinant human calreticulinIntracellular proteinsCalcium-binding chaperoneDifferent cell typesRecombinant formTranscription factorsFusion of monocytesExtracellular functionsNew therapeutic opportunitiesK activityCathepsin K activityCell typesCalreticulinCytoplasmic 1Anti-osteoclastogenic effectPrecursor cellsMetastatic bone cancerFactor 1Human calreticulinActivated T cellsOsteoclast precursor cellsProteinNuclear factorC-fosMouse calvarial bones
2014
Proteomic identification of 14‐3‐3ϵ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells
Kim KO, Hsu AC, Lee HG, Patel N, Chandhanayingyong C, Hickernell T, Lee F. Proteomic identification of 14‐3‐3ϵ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells. Journal Of Orthopaedic Research® 2014, 32: 848-854. PMID: 24536031, DOI: 10.1002/jor.22598.Peer-Reviewed Original ResearchConceptsPERK1/2 inhibitionHuman osteosarcoma cellsBim expressionSubset of patientsOsteosarcoma cellsConventional cytotoxic agentsConventional cytotoxic treatmentAnti-cancer effectsInhibition of pERK1/2Pro-apoptotic mechanismsMultifocal osteosarcomaMultimodality chemotherapyCytotoxic treatmentUpregulation of BimOsteosarcoma treatmentOsteosarcoma cell deathCytotoxic agentsExpression of BimPotential mediatorsTreatment of PD98059UpregulationTreatmentPD98059 treatmentInhibitionCell death